Switch theme
Sign up to access all valuation multiples
Integral Diagnostics is Australia’s fourth-largest diagnostic imaging provider. In Australia, imaging revenues are almost entirely earned via the public health Medicare system. Integral typically earns approximately 90% of group revenue from diagnostic imaging in Australia and the remainder from diagnostic imaging in Auckland, New Zealand. In Australia, Integral services regional areas in Queensland, Victoria, New South Wales, and Western Australia.
2008
2.0K+
LTM Revenue $407M
LTM EBITDA $77.8M
$901M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Integral Diagnostics has a last 12-month revenue (LTM) of $407M and a last 12-month EBITDA of $77.8M.
In the most recent fiscal year, Integral Diagnostics achieved revenue of $302M and an EBITDA of $4.3M.
Integral Diagnostics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Integral Diagnostics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $407M | XXX | $302M | XXX | XXX | XXX |
| Gross Profit | $395M | XXX | $287M | XXX | XXX | XXX |
| Gross Margin | 97% | XXX | 95% | XXX | XXX | XXX |
| EBITDA | $77.8M | XXX | $4.3M | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 1% | XXX | XXX | XXX |
| EBIT | $41.5M | XXX | $27.1M | XXX | XXX | XXX |
| EBIT Margin | 10% | XXX | 9% | XXX | XXX | XXX |
| Net Profit | $18.3M | XXX | -$39.0M | XXX | XXX | XXX |
| Net Margin | 5% | XXX | -13% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $115M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Integral Diagnostics's stock price is AUD 2 (or $2).
Integral Diagnostics has current market cap of AUD 901M (or $579M), and EV of AUD 1.4B (or $901M).
See Integral Diagnostics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $901M | $579M | XXX | XXX | XXX | XXX | $0.06 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Integral Diagnostics has market cap of $579M and EV of $901M.
Integral Diagnostics's trades at 2.5x EV/Revenue multiple, and 21.5x EV/EBITDA.
Equity research analysts estimate Integral Diagnostics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Integral Diagnostics has a P/E ratio of 31.6x.
See valuation multiples for Integral Diagnostics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $579M | XXX | $579M | XXX | XXX | XXX |
| EV (current) | $901M | XXX | $901M | XXX | XXX | XXX |
| EV/Revenue | 2.2x | XXX | 2.5x | XXX | XXX | XXX |
| EV/EBITDA | 11.6x | XXX | 21.5x | XXX | XXX | XXX |
| EV/EBIT | 21.7x | XXX | 25.8x | XXX | XXX | XXX |
| EV/Gross Profit | 2.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 31.6x | XXX | -57.7x | XXX | XXX | XXX |
| EV/FCF | 41.7x | XXX | 37.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialIntegral Diagnostics's last 12 month revenue growth is 25%
Integral Diagnostics's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Integral Diagnostics's rule of 40 is 36% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Integral Diagnostics's rule of X is 83% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Integral Diagnostics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 25% | XXX | 22% | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Growth | 37% | XXX | 72% | XXX | XXX | XXX |
| Rule of 40 | 36% | XXX | 37% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 83% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 86% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Burjeel Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| PureHealth | XXX | XXX | XXX | XXX | XXX | XXX |
| Ramsay Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Athens Medical Centre | XXX | XXX | XXX | XXX | XXX | XXX |
| Compass Pathways | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Integral Diagnostics acquired XXX companies to date.
Last acquisition by Integral Diagnostics was XXXXXXXX, XXXXX XXXXX XXXXXX . Integral Diagnostics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Integral Diagnostics founded? | Integral Diagnostics was founded in 2008. |
| Where is Integral Diagnostics headquartered? | Integral Diagnostics is headquartered in Australia. |
| How many employees does Integral Diagnostics have? | As of today, Integral Diagnostics has 2.0K+ employees. |
| Who is the CEO of Integral Diagnostics? | Integral Diagnostics's CEO is Dr. Ian Kadish. |
| Is Integral Diagnostics publicy listed? | Yes, Integral Diagnostics is a public company listed on ASX. |
| What is the stock symbol of Integral Diagnostics? | Integral Diagnostics trades under IDX ticker. |
| When did Integral Diagnostics go public? | Integral Diagnostics went public in 2015. |
| Who are competitors of Integral Diagnostics? | Similar companies to Integral Diagnostics include e.g. Burjeel Holdings, PureHealth, Ramsay Health, Athens Medical Centre. |
| What is the current market cap of Integral Diagnostics? | Integral Diagnostics's current market cap is $579M |
| What is the current revenue of Integral Diagnostics? | Integral Diagnostics's last 12 months revenue is $407M. |
| What is the current revenue growth of Integral Diagnostics? | Integral Diagnostics revenue growth (NTM/LTM) is 25%. |
| What is the current EV/Revenue multiple of Integral Diagnostics? | Current revenue multiple of Integral Diagnostics is 2.2x. |
| Is Integral Diagnostics profitable? | Yes, Integral Diagnostics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Integral Diagnostics? | Integral Diagnostics's last 12 months EBITDA is $77.8M. |
| What is Integral Diagnostics's EBITDA margin? | Integral Diagnostics's last 12 months EBITDA margin is 19%. |
| What is the current EV/EBITDA multiple of Integral Diagnostics? | Current EBITDA multiple of Integral Diagnostics is 11.6x. |
| What is the current FCF of Integral Diagnostics? | Integral Diagnostics's last 12 months FCF is $21.6M. |
| What is Integral Diagnostics's FCF margin? | Integral Diagnostics's last 12 months FCF margin is 5%. |
| What is the current EV/FCF multiple of Integral Diagnostics? | Current FCF multiple of Integral Diagnostics is 41.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
